Lynparza

News

Lynparza on cusp of approval for advanced ovarian cancer

Breast cancer drug Lynparza (olaparib) is poised for EU approval for the first-line treatment of a certain type of metastatic ovarian cancer.

News

AZ and MSD’s Lynparza gets EU nod for hard-to-treat breast c...

The European Commission has approved AstraZeneca and MSD’s Lynparza (olaparib) for the treatment of germline BRCA-mutated HER2-negative advanced breast cancer – making it the first drug app

R&D

AstraZeneca cancer drugs approved in Japan

AstraZeneca secured a fast approval of lung and breast cancer drugs with usually sluggish Japanese regulators, just months after scoring similar approvals in

News